MedTrace Logo

A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

NCT05604898 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2022-11-08

No results posted yet for this study

Summary

The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.

Conditions

Interventions

DRUG

Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

608 will be administered subcutaneously.

OTHER

Placebo

Participants will receive Placebo to maintain the blinding of the Investigational Medicinal Products.

DRUG

Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection

608 will be provided at pre-specified time intervals.

OTHER

Placebo

Participants will receive Placebo at pre-specified time points to maintain the blinding of the Investigational Medicinal Products.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jinhua Xu, MD · Shanghai Huanshan Hospital Fudan University-Dermatology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-05-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05604898 on ClinicalTrials.gov